Article

Bilateral treatment for mild-to-moderate hyperopia promising

Washington, DC &#8212 Good near and distance visual acuity may be achieved in mild-to-moderate hyperopia in patients using a bilateral treatment approach, reported Marguerite B. McDonald, MD, who spoke at a refractive symposium on hyperopia, conductive keratoplasty (CK, Refractec), and LASIK during the American Society of Cataract and Refractive Surgery annual meeting.

April 19 - Washington, DC - Good near and distance visual acuity may be achieved in mild-to-moderate hyperopia in patients using a bilateral treatment approach, reported Marguerite B. McDonald, MD, who spoke at a refractive symposium on hyperopia, conductive keratoplasty (CK, Refractec), and LASIK during the American Society of Cataract and Refractive Surgery annual meeting.

Dr. McDonald, clinical professor of ophthalmology, Tulane University School of Medicine, New Orleans, presented the results of a small retrospective case series in which patients with hyperopia were treated with CK for distance in one eye and hyperopic LASEK for near in the other eye with the VISX STAR S4 excimer laser.

The advantage of CK, a thermokeratoplasty technique used to reshape the cornea, is that it is less invasive than LASIK and can increase multifocality without the loss of contrast sensitivity, Dr. McDonald explained.

"Larger corrections are possible with CK," she continued. "It has less impact on dry eye than LASIK. There are no concerns regarding exposure in these small deep-set, hyperopic eyes. Useful vision returns within 3 to 5 days."

In this series of 16 patients, the preoperative mean uncorrected visual acuity in the CK eyes for distance was 20/50 (range, 20/20 to 20/80). At 3 months postoperatively, the UCVA for distance in the CK eyes was 20/20 or better in 70% of the eyes and 20/40 or better in 90%, she noted.

The near acuity in the CK eyes corrected for distance improved from J12 to J3 at 3 months postoperatively. In addition, there was no increase in cylinder in these eyes. In fact, 63% had no cylinder and 78% had less than 0.5 D of cylinder.

"There was a statistically significant change in higher-order aberrations (HOA) at 1 month. Everything returned to baseline at 3 months, except for spherical aberrations, which had a statistically significant improvement at 3 months," Dr. McDonald said.

In the eyes treated with alcohol-free LASEK for near, the mean UCVA was 20/25 (range 20/20 to 20/40). Half of these eyes had a near UCVA of 20/20 or better and were not corrected for near, Dr. McDonald said. The mean UCVA at distance in these eyes was 20/40. Forty percent of these eyes achieve better than 20/40 UCVA at distance postoperatively compared with only 12% preoperatively.

At 3 months postoperatively, the LASEK-treated eyes for near had no increase in cylinder and 75% had no cylinder at all. In addition, the HOA change at 1 month was statistically significant and then returned to baseline at 3 months, except for an improvement in spherical equivalent at both 1 and 3 months.

This combination approach provides hyperopic patients with excellent UCVA at near and distance and is especially useful if more than 2 D of vision correction is needed. This bilateral treatment is beneficial in terms of HOA. However, more study is need, Dr. McDonald said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.